• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

影响斑片状斑秃局部治疗反应的预后因素。

Prognostic factors that affect the response to topical treatment in patchy alopecia areata.

机构信息

Elazig Education and Research Hospital Department of Dermatology, TR23119 Elazig, TurkeyFirat University Faculty of Medicine, Departments of Dermatology.

出版信息

J Eur Acad Dermatol Venereol. 2014 Jan;28(1):34-40. doi: 10.1111/jdv.12043. Epub 2012 Nov 26.

DOI:10.1111/jdv.12043
PMID:23181708
Abstract

BACKGROUND

Alopecia areata (AA) is an organ-specific, T-cell-mediated autoimmune disease that is characterized by non-scarring hair loss.

OBJECTIVE

We aimed to find the factors that may affect the response to topical therapy in AA.

METHODS

The study included a total of 60 patients with AA and 30 healthy control patients. The AA patients were randomized into two groups. 40 patients used 0.05% clobetasol propionate cream, and 20 patients used petrolatum (placebo). Both groups applied topical treatments to their lesions twice daily for 12 weeks.

RESULTS

The mean extent of AA was 21.88 ± 16.75% in patients with autoantibodies and 12.16 ± 13.55% in those who were negative for autoantibodies (P = 0.021). Ophiasic pattern and nail involvement were observed more frequently in patients with atopy (P < 0.05). Relapse was more frequent in patients with atopy (P = 0.002) and nail involvement (P = 0.02).

CONCLUSIONS

We observed that the presence of autoantibodies was associated with more extensive AA, and that ophiasic hair loss pattern and nail dystrophy were significantly associated with atopy. Topical clobetasol propionate treatment produced a modest advantage in hair regrowth as compared with placebo. Notably, atopic AA patients have a higher risk of relapse and redevelopment of AA after completing a course of topical corticosteroid treatment.

摘要

背景

斑秃(AA)是一种器官特异性、T 细胞介导的自身免疫性疾病,其特征是无瘢痕性脱发。

目的

我们旨在寻找可能影响 AA 局部治疗反应的因素。

方法

本研究共纳入 60 例 AA 患者和 30 例健康对照患者。AA 患者随机分为两组。40 例患者使用 0.05%丙酸氯倍他索乳膏,20 例患者使用凡士林(安慰剂)。两组患者均每日两次将局部治疗药物涂抹于皮损处,共 12 周。

结果

自身抗体阳性患者 AA 的平均严重程度为 21.88±16.75%,自身抗体阴性患者 AA 的严重程度为 12.16±13.55%(P=0.021)。特应性患者中更常观察到蛇形发和甲受累(P<0.05)。特应性患者(P=0.002)和甲受累患者(P=0.02)更易复发。

结论

我们发现自身抗体的存在与 AA 更广泛有关,蛇形脱发模式和甲营养不良与特应性显著相关。与安慰剂相比,外用氯倍他索丙酸酯治疗在毛发生长方面有适度优势。值得注意的是,特应性 AA 患者在完成局部皮质类固醇治疗后,复发和 AA 再次发生的风险更高。

相似文献

1
Prognostic factors that affect the response to topical treatment in patchy alopecia areata.影响斑片状斑秃局部治疗反应的预后因素。
J Eur Acad Dermatol Venereol. 2014 Jan;28(1):34-40. doi: 10.1111/jdv.12043. Epub 2012 Nov 26.
2
Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial.一种新型0.05%丙酸氯倍他索泡沫剂治疗斑秃的疗效与安全性:一项随机、双盲、安慰剂对照试验
J Eur Acad Dermatol Venereol. 2006 Nov;20(10):1243-7. doi: 10.1111/j.1468-3083.2006.01781.x.
3
Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in children: a randomized clinical trial.丙酸氯倍他索 0.05%对比氢化可的松 1%治疗儿童斑秃:一项随机临床试验。
JAMA Dermatol. 2014 Jan;150(1):47-50. doi: 10.1001/jamadermatol.2013.5764.
4
The comparison of treatment with clobetasol propionate 0.05% and topical pimecrolimus 1% treatment in the treatment of alopecia areata.比较 0.05%丙酸氯倍他索和 1%吡美莫司乳膏治疗斑秃的疗效。
J Dermatolog Treat. 2012 Dec;23(6):410-20. doi: 10.3109/09546634.2011.590788. Epub 2011 Jul 25.
5
Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis.0.05%丙酸氯倍他索封包治疗全秃/普秃
J Am Acad Dermatol. 2003 Jul;49(1):96-8. doi: 10.1067/mjd.2003.423.
6
Combined oral pulse and topical corticosteroid therapy for severe alopecia areata in children: a long-term follow-up study.儿童重度斑秃的联合口服脉冲与外用皮质类固醇激素治疗:一项长期随访研究
Dermatol Ther. 2015 Sep-Oct;28(5):309-17. doi: 10.1111/dth.12255. Epub 2015 Jul 16.
7
Efficacy and safety of diphenylcyclopropenone among Chinese patients with steroid resistant and extensive alopecia areata.二苯环丙烯酮治疗中国难治性和广泛型斑秃患者的疗效和安全性。
J Eur Acad Dermatol Venereol. 2013 Mar;27(3):e400-5. doi: 10.1111/jdv.12009. Epub 2012 Oct 12.
8
The comparison of therapeutic effect of Clobetasol propionate lotion and squill extract in alopecia areata: a randomized, double-blind clinical trial.丙酸氯倍他索洗剂与斑蝥素搽剂治疗斑秃的疗效比较:一项随机、双盲临床试验。
Arch Dermatol Res. 2020 Apr;312(3):173-178. doi: 10.1007/s00403-019-02004-w. Epub 2019 Nov 9.
9
Alopecia areata: an update.斑秃:更新。
Indian J Dermatol Venereol Leprol. 2013 Sep-Oct;79(5):563-75. doi: 10.4103/0378-6323.116725.
10
Topical Calcipotriol Therapy for Mild-to-Moderate Alopecia Areata: A Retrospective Study.外用卡泊三醇治疗轻度至中度斑秃:一项回顾性研究。
J Drugs Dermatol. 2015 Jun;14(6):616-20.

引用本文的文献

1
Clinical Profile and Predictors of Relapse in Patients with Alopecia Areata: A Follow-Up Study.斑秃患者的临床特征及复发预测因素:一项随访研究
Indian J Dermatol. 2024 Jul-Aug;69(4):344-346. doi: 10.4103/ijd.ijd_1060_21. Epub 2024 Aug 19.
2
Treatments for alopecia areata: a network meta-analysis.斑秃治疗方法的网状荟萃分析。
Cochrane Database Syst Rev. 2023 Oct 23;10(10):CD013719. doi: 10.1002/14651858.CD013719.pub2.
3
A Retrospective Review of Anthralin in Petrolatum in the Treatment of Alopecia Areata in the Pediatric Population.
回顾性研究蒽林-凡士林在儿童斑秃治疗中的应用。
J Cutan Med Surg. 2023 Sep-Oct;27(5):449-453. doi: 10.1177/12034754231191060. Epub 2023 Aug 9.
4
Alopecia Areata Sisaipho: Clinical and Therapeutic Approach in 13 Patients in Spain.斑秃西赛福:西班牙13例患者的临床与治疗方法
Int J Trichology. 2016 Apr-Jun;8(2):99-100. doi: 10.4103/0974-7753.188039.